MX336996B - Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor. - Google Patents

Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor.

Info

Publication number
MX336996B
MX336996B MX2012007756A MX2012007756A MX336996B MX 336996 B MX336996 B MX 336996B MX 2012007756 A MX2012007756 A MX 2012007756A MX 2012007756 A MX2012007756 A MX 2012007756A MX 336996 B MX336996 B MX 336996B
Authority
MX
Mexico
Prior art keywords
triazolopyrazines
compositions
methods
use therefor
triazolopyridines
Prior art date
Application number
MX2012007756A
Other languages
Spanish (es)
Other versions
MX2012007756A (en
Inventor
Wei-Guo Su
Hong Jia
Guangxiu Dai
Original Assignee
Hutchison Medipharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44226181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX336996(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hutchison Medipharma Ltd filed Critical Hutchison Medipharma Ltd
Publication of MX2012007756A publication Critical patent/MX2012007756A/en
Publication of MX336996B publication Critical patent/MX336996B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)

Abstract

Provided are certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor.
MX2012007756A 2009-12-31 2010-12-30 Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor. MX336996B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2009076321 2009-12-31
PCT/CN2010/080499 WO2011079804A1 (en) 2009-12-31 2010-12-30 Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor

Publications (2)

Publication Number Publication Date
MX2012007756A MX2012007756A (en) 2012-11-06
MX336996B true MX336996B (en) 2016-02-09

Family

ID=44226181

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012007756A MX336996B (en) 2009-12-31 2010-12-30 Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor.

Country Status (38)

Country Link
US (8) US8987269B2 (en)
EP (5) EP2519524A4 (en)
JP (5) JP5337313B2 (en)
KR (3) KR101905350B1 (en)
CN (3) CN106117248B (en)
AU (2) AU2010338712B2 (en)
BR (1) BR112012016129B1 (en)
CA (1) CA2785749C (en)
CL (1) CL2012001752A1 (en)
CO (1) CO6612235A2 (en)
CU (1) CU24167B1 (en)
CY (2) CY1118250T1 (en)
DK (3) DK3795573T3 (en)
DO (1) DOP2012000188A (en)
EA (2) EA025466B1 (en)
EC (1) ECSP12012011A (en)
ES (4) ES2840454T3 (en)
GT (1) GT201200220A (en)
HK (2) HK1194071A1 (en)
HR (3) HRP20221090T1 (en)
HU (3) HUE059696T2 (en)
IL (2) IL220433B (en)
LT (1) LT3795573T (en)
ME (1) ME02211B (en)
MX (1) MX336996B (en)
MY (1) MY179933A (en)
NI (1) NI201200118A (en)
NZ (1) NZ601128A (en)
PE (3) PE20160588A1 (en)
PL (3) PL3795573T3 (en)
PT (3) PT3795573T (en)
RS (3) RS63612B1 (en)
SG (1) SG181781A1 (en)
SI (2) SI3511330T1 (en)
SM (1) SMT201500213B (en)
UA (1) UA107822C2 (en)
WO (1) WO2011079804A1 (en)
ZA (1) ZA201205730B (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101905350B1 (en) 2009-12-31 2018-11-30 허치슨 메디파르마 리미티드 Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor
JP5960688B2 (en) 2010-05-17 2016-08-02 インコゼン セラピューティクス プライベート リミテッド Novel 3,5-disubstituted-3H- [1,2,3] triazolo [4,5-B] pyridine compounds as protein kinase modulators
CN103030654A (en) * 2011-10-09 2013-04-10 济南赛文医药技术有限公司 Micromolecular c-Met protein kinase inhibitor
CN102516046A (en) * 2011-11-22 2012-06-27 太仓市运通化工厂 Method for synthesizing 2-bromopropanal
MY169268A (en) * 2012-03-30 2019-03-20 Rhizen Pharmaceuticals S A Novel 3,5-disubstituted-3h-imidazo[4,5-b]pyridine and 3,5-disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of c-met protein kinases
CA2776178A1 (en) 2012-04-05 2013-10-05 Hydro-Quebec Ionic compounds
KR101745741B1 (en) 2012-08-13 2017-06-12 한국화학연구원 Novel Triazolopyrazine Derivatives and Use Thereof
RU2655604C2 (en) * 2013-01-11 2018-05-29 Фуджифилм Корпорэйшн Nitrogen-containing heterocyclic compound or salt thereof
LT2964638T (en) 2013-03-06 2017-12-27 Astrazeneca Ab Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
CN103265468A (en) * 2013-06-17 2013-08-28 连云港盛和生物科技有限公司 Synthetic method of 2,4-dimethyl-1H-pyrrole-3-carboxylic acid ethyl ester
EP2818471A1 (en) * 2013-06-27 2014-12-31 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Nitrogen bicyclic compounds as inhibitors for Scyl1 and Grk5
DK3053923T3 (en) * 2013-09-30 2018-07-23 Korea Res Inst Chemical Tech TRIAZOLOPYRAZINE DERIVATIVES AS TYROSIN KINASE INHIBITORS
EA201890061A3 (en) * 2013-12-26 2018-09-28 Игнита, Инк. PYRAZOLO [1,5-A] PYRIDINE DERIVATIVES AND METHODS OF THEIR APPLICATION
JP2016048495A (en) * 2014-08-28 2016-04-07 京セラ株式会社 Portable terminal, recommendation program, recommendation system, and recommendation method
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
EP3340983B1 (en) 2015-08-26 2023-10-04 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
WO2017114452A1 (en) * 2015-12-31 2017-07-06 上海医药集团股份有限公司 Salt of quinolone compound, polymorphs thereof, preparation method therefor, composition, and applications
GB201616116D0 (en) 2016-09-22 2016-11-09 Astrazeneca Ab Use of c-Met inhibitors to treat cancers harbouring MET mutations
KR20180092096A (en) * 2017-02-08 2018-08-17 에이비온 주식회사 Novel Polymorphic Forms of Triazolopyrazine Derivatives and Processes of Manufacturing Thereof
EP3589287B1 (en) 2017-03-01 2022-09-14 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for treatment of medical disorders
CN110603252A (en) 2017-03-01 2019-12-20 艾其林医药公司 Aryl, heteroaryl and heterocyclic pharmaceutical compounds for the treatment of medical disorders
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
CN108570053A (en) * 2017-03-13 2018-09-25 中国科学院上海药物研究所 Five yuan and 6-membered heterocyclic compound, preparation method, intermediate, combination and application
KR101924801B1 (en) 2017-08-16 2018-12-04 한국원자력의학원 Composition for preventing or treating cancer comprising triazolopyridine derivatives
HU231333B1 (en) 2018-07-13 2023-01-28 Richter Gedeon Nyrt Spirochromane derivatives
JP7443375B2 (en) 2018-09-06 2024-03-05 アキリオン ファーマシューティカルズ， インコーポレーテッド Macrocyclic compounds for the treatment of medical disorders
MX2021002640A (en) 2018-09-06 2021-07-16 Achillion Pharmaceuticals Inc Morphic forms of complement factor d inhibitors.
WO2020053198A1 (en) * 2018-09-11 2020-03-19 Astrazeneca Ab Improved method for the manufacture of 3-[(1s)-1-imidazo[1,2-a]pyridin-6-ylethyl]-5-(1-methylpyrazol-4-yl)triazolo[4,5-b]pyrazine and polymorphic forms thereof
CN112996497A (en) 2018-09-25 2021-06-18 艾其林医药公司 Morphic forms of complement factor D inhibitors
SG11202104460UA (en) * 2018-10-30 2021-05-28 Repare Therapeutics Inc Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors
CN113412112B (en) 2018-12-14 2024-06-11 贝达医药公司 Organophosphorus substituted compounds as c-MET inhibitors and therapeutic uses thereof
JP2022541825A (en) * 2019-07-22 2022-09-27 リペア セラピューティクス インコーポレイテッド Substituted 2-morpholinopyridine derivatives as ATR kinase inhibitors
WO2021168320A1 (en) * 2020-02-20 2021-08-26 Achillion Pharmaceuticals, Inc. Heteroaryl compounds for treatment of complement factor d mediated disorders
WO2021229605A1 (en) * 2020-05-14 2021-11-18 Dr. Reddy's Laboratories Limited Process for preparation of savolitinib and its intermediates
IL301146A (en) * 2020-09-28 2023-05-01 Codexis Inc Engineered biocatalysts and methods for synthesizing chiral amines
JP2023554393A (en) * 2020-12-16 2023-12-27 アイエフエム デュー インコーポレイテッド Compounds and compositions for treating conditions associated with STING activity
KR102659095B1 (en) 2021-01-08 2024-04-19 에이비온 주식회사 Method for preparing pharmaceutical formulation of tablet containing triazolopyrazine derivative as an active ingredient
CN113278019A (en) * 2021-05-31 2021-08-20 河南偶联生物科技有限公司 Synthesis method of imidazo [1,2-A ] pyridine compound
AU2023258030A1 (en) * 2022-04-20 2024-10-17 Engrail Therapeutics, Inc. Gabaa receptor modulator salts, particles, and uses thereof
WO2024008929A1 (en) 2022-07-08 2024-01-11 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors in combination with hgf-receptor inhibitors for the treatment of cancer
WO2024026410A2 (en) * 2022-07-29 2024-02-01 Baylor College Of Medicine Neurotrophic receptor tyrosine kinase (ntrk) inhibitors and methods using same
CN115611802B (en) * 2022-12-02 2023-03-14 北京迪泰医药科技有限公司 Synthetic method of 3-acetyl-2-chloropyridine
WO2024148089A1 (en) * 2023-01-04 2024-07-11 Blueprint Medicines Corporation Cdk2 inhibitors
GB202300923D0 (en) * 2023-01-20 2023-03-08 Macfarlan Smith Ltd Novel polymorphic forms of savolitinib

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4444762A (en) 1980-04-04 1984-04-24 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclopentan-2-ones
US5977134A (en) * 1996-12-05 1999-11-02 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US7674791B2 (en) 2003-04-09 2010-03-09 Biogen Idec Ma Inc. Triazolopyrazines and methods of making and using the same
US6979505B2 (en) * 2003-06-09 2005-12-27 Utc Fuel Cells, Llc Method and apparatus for removal of contaminants from a hydrogen processor feed stream, as in a fuel cell power plant
CA2530589A1 (en) * 2003-07-02 2005-01-20 Sugen Inc. Arylmethyl triazolo and imidazopyrazines as c-met inhibitors
US7122548B2 (en) 2003-07-02 2006-10-17 Sugen, Inc. Triazolotriazine compounds and uses thereof
CA2537916A1 (en) 2003-09-03 2005-03-31 Neurogen Corporation 5-aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds
AU2005269386A1 (en) 2004-07-27 2006-02-09 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
CA2577478A1 (en) 2004-08-18 2006-02-23 Pharmacia & Upjohn Company Llc Triazolopyridine compounds
DK1853602T3 (en) * 2005-02-16 2010-09-20 Astrazeneca Ab Chemical compounds
CN101119996A (en) * 2005-02-16 2008-02-06 阿斯利康(瑞典)有限公司 chemical compound
WO2007064797A2 (en) * 2005-11-30 2007-06-07 Vertex Pharmaceuticals Incorporated Inhibitors of c-met and uses thereof
US8030305B2 (en) 2005-12-21 2011-10-04 Janssen Pharmaceutica N.V. Triazolopyridazines as kinase modulators
NL2000613C2 (en) 2006-05-11 2007-11-20 Pfizer Prod Inc Triazole pyrazine derivatives.
WO2007138472A2 (en) 2006-05-30 2007-12-06 Pfizer Products Inc. Triazolopyridazine derivatives
PE20080403A1 (en) * 2006-07-14 2008-04-25 Amgen Inc FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
EP2057164A1 (en) 2006-08-07 2009-05-13 Incyte Corporation Triazolotriazines as kinase inhibitors
NZ575548A (en) 2006-09-18 2011-09-30 Vertex Pharma Heterocyclic inhibitors of c-Met and uses thereof
JP5378222B2 (en) 2006-10-23 2013-12-25 エスジーエックス ファーマシューティカルズ、インコーポレイテッド Bicyclic triazoles as protein kinase modulators
ES2393132T3 (en) * 2006-10-23 2012-12-18 Sgx Pharmaceuticals, Inc. Triazolopyridazine protein kinase modules
HUE026659T2 (en) 2006-11-22 2016-07-28 Incyte Holdings Corp Imidazotriazines and imidazopyrimidines as kinase inhibitors
CA2683398A1 (en) 2007-04-10 2008-10-16 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
US8148369B2 (en) 2007-05-10 2012-04-03 Janssen Pharmaceutica Nv Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases
PA8792501A1 (en) 2007-08-09 2009-04-23 Sanofi Aventis NEW DERIVATIVES OF 6-TRIAZOLOPIRIDACINA-SULFANIL BENZOTIAZOL AND BENCIMIDAZOL, ITS PREPARATION PROCEDURE, ITS APPLICATION AS MEDICATIONS, PHARMACEUTICAL COMPOSITIONS AND NEW MAIN USE AS MET INHIBITORS.
MX2010009414A (en) 2008-02-28 2010-09-24 Novartis Ag Imidazo [1,2-b] pyridazine derivatives for the treatment of c-met tyrosine kinase mediated disease.
US8691838B2 (en) 2008-05-22 2014-04-08 Amgen Inc. Heterocycles as protein kinase inhibitors
DE102008037790A1 (en) 2008-08-14 2010-02-18 Merck Patent Gmbh Bicyclic triazole derivatives
UY32049A (en) 2008-08-14 2010-03-26 Takeda Pharmaceutical CMET INHIBITORS
AU2010283806A1 (en) * 2009-08-12 2012-03-01 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
BR112012008061A2 (en) * 2009-08-20 2016-03-01 Novartis Ag heterocyclic oxime compounds
KR101905350B1 (en) * 2009-12-31 2018-11-30 허치슨 메디파르마 리미티드 Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor
JP5960688B2 (en) 2010-05-17 2016-08-02 インコゼン セラピューティクス プライベート リミテッド Novel 3,5-disubstituted-3H- [1,2,3] triazolo [4,5-B] pyridine compounds as protein kinase modulators

Also Published As

Publication number Publication date
US8987269B2 (en) 2015-03-24
US10512645B2 (en) 2019-12-24
EP2719699A1 (en) 2014-04-16
ES2546635T3 (en) 2015-09-25
US20120245178A1 (en) 2012-09-27
PT3795573T (en) 2022-09-15
CN106117248B (en) 2019-01-22
PL2719699T3 (en) 2016-01-29
KR101434766B1 (en) 2014-08-26
KR101771299B1 (en) 2017-08-24
CN102906092B (en) 2016-08-03
US20210154192A1 (en) 2021-05-27
HUE059696T2 (en) 2022-12-28
US11896592B2 (en) 2024-02-13
KR20120125261A (en) 2012-11-14
ES2927146T3 (en) 2022-11-02
HK1216880A1 (en) 2016-12-09
CU24167B1 (en) 2016-03-31
WO2011079804A1 (en) 2011-07-07
CN106117248A (en) 2016-11-16
JP2013516393A (en) 2013-05-13
SG181781A1 (en) 2012-07-30
IL239997A (en) 2017-11-30
ME02211B (en) 2016-02-20
JP2019108345A (en) 2019-07-04
CN102906092A (en) 2013-01-30
PT3511330T (en) 2020-12-24
MX2012007756A (en) 2012-11-06
IL239997A0 (en) 2015-08-31
AU2015203480A1 (en) 2015-07-16
HRP20150952T1 (en) 2015-10-09
NZ601128A (en) 2014-12-24
JP5337313B2 (en) 2013-11-06
AU2015203480B2 (en) 2017-10-26
LT3795573T (en) 2022-11-10
CU20120101A7 (en) 2012-10-15
UA107822C2 (en) 2015-02-25
US20180263977A1 (en) 2018-09-20
US8507487B2 (en) 2013-08-13
AU2010338712A1 (en) 2012-07-12
BR112012016129B1 (en) 2020-11-03
HUE025504T2 (en) 2016-02-29
KR20140059307A (en) 2014-05-15
EA201200951A1 (en) 2013-09-30
RS63612B1 (en) 2022-10-31
GT201200220A (en) 2014-12-22
BR112012016129A2 (en) 2016-05-31
CA2785749C (en) 2017-11-28
PT2719699E (en) 2015-09-30
US20200179377A1 (en) 2020-06-11
EP2719699B1 (en) 2015-07-08
CL2012001752A1 (en) 2013-01-25
JP6647434B2 (en) 2020-02-14
JP2018009004A (en) 2018-01-18
NI201200118A (en) 2013-01-24
PE20211094A1 (en) 2021-06-14
EP3511330B1 (en) 2020-09-30
PL3795573T3 (en) 2022-11-21
US20170027934A1 (en) 2017-02-02
DK3511330T3 (en) 2020-12-21
CN106432225B (en) 2019-02-19
EP2519524A4 (en) 2013-07-03
US20240139182A1 (en) 2024-05-02
EP3511330A1 (en) 2019-07-17
CN106432225A (en) 2017-02-22
HRP20221090T1 (en) 2022-11-25
EA030141B1 (en) 2018-06-29
JP6194046B2 (en) 2017-09-06
JP2016155848A (en) 2016-09-01
EP2519524A1 (en) 2012-11-07
PE20160588A1 (en) 2016-07-09
EP3795573A1 (en) 2021-03-24
JP2013209418A (en) 2013-10-10
DK2719699T3 (en) 2015-08-24
EA025466B1 (en) 2016-12-30
EP2966075B1 (en) 2019-02-27
PE20130375A1 (en) 2013-04-10
HUE052828T2 (en) 2021-05-28
RS61281B1 (en) 2021-02-26
HK1194071A1 (en) 2014-10-10
ZA201205730B (en) 2016-01-27
HRP20202017T1 (en) 2021-02-19
KR20170098324A (en) 2017-08-29
ES2726152T3 (en) 2019-10-02
RS54217B1 (en) 2015-12-31
SI2719699T1 (en) 2015-12-31
DK3795573T3 (en) 2022-09-19
SI3511330T1 (en) 2021-01-29
EP2966075A1 (en) 2016-01-13
PL3511330T3 (en) 2021-04-19
ECSP12012011A (en) 2012-10-30
US20150368271A1 (en) 2015-12-24
AU2010338712B2 (en) 2015-04-02
KR101905350B1 (en) 2018-11-30
EP3795573B1 (en) 2022-07-06
CY1118250T1 (en) 2017-06-28
EA201691461A1 (en) 2017-01-30
CA2785749A1 (en) 2011-07-07
CY1123777T1 (en) 2022-03-24
US9956218B2 (en) 2018-05-01
SMT201500213B (en) 2015-10-30
MY179933A (en) 2020-11-19
IL220433B (en) 2018-01-31
DOP2012000188A (en) 2012-12-31
ES2840454T3 (en) 2021-07-06
US20120264739A1 (en) 2012-10-18
US10946014B2 (en) 2021-03-16
JP6486999B2 (en) 2019-03-20
CO6612235A2 (en) 2013-02-01

Similar Documents

Publication Publication Date Title
MY179933A (en) Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use thereof
IN2012DN00548A (en)
IN2012DN00746A (en)
MX344786B (en) Compositions and methods for treating gaucher disease.
MX2012006549A (en) Compositions and methods comprising protease variants.
UA118328C2 (en) Targeted gemomic alteration
MX2013002784A (en) Fused heteroaryls and their uses.
MX2012007507A (en) Heteroaryl compounds and uses thereof.
EP2569330A4 (en) Chlorotoxin variants, conjugates, and methods for their use
CR20120362A (en) CERTAIN TRIAZOLOPIRIDINS AND TRIAZOLOPIRAZINS, COMPOSITIONS OF THESE AND THEIR EMPLOYMENT METHODS
MX2011014019A (en) Diazahomoadamantane derivatives and methods of use thereof.
MY161601A (en) Films and compositions comprising the same
MX2013007230A (en) Polymer systems.
IN2012DN03404A (en)
SG178865A1 (en) Cartilage repair
MX2013008559A (en) Leptin derivatives.
UA41660U (en) Use of jacton and mexidol as actoprotector
AU326123S (en) Dress
UA35660U (en) Use of antihomotoxic preparations as cytoprotectors
UA52379U (en) use of lipine as agent with frigoprotective action
UA52378U (en) use of lipoflavon as agent with frigoprotective action
UA52376U (en) use of corvitine as agent with frigoprotective action
UA59797U (en) Use of amcesol as antitussive substance
UA36194U (en) Use of quercetin as hepatoprotector
CL2009001549S1 (en) Armchair.

Legal Events

Date Code Title Description
FG Grant or registration